Amarpali Brar, MD
Nephrology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 6
- Since medical school
- 23 years
- Graduated 2003
Offices
6 locations · UCSF Medical Group Business Services · 1,533 clinicians in this group
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Brar’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C154027 · Current
Licensed to practise in California · since 2018 · expires 2027-11-30 · Baba Farid University of Health Sciences Government Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Nephrology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$72,135
Medicare paid this office $72,135 for 283 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 145 | $36,183 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $9,610 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $6,995 | $104 |
| New patient visit (60+ min) | 26 | $3,852 | $148 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 131 | $3,517 | $14 |
See all 8 services
| Long return visit (40+ min) | 145 | $36,183 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $9,610 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $6,995 | $104 |
| New patient visit (60+ min) | 26 | $3,852 | $148 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 131 | $3,517 | $14 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,337 | $115 |
| Telephone medical discussion with physician, 21-30 minutes | 29 | $3,208 | $75 |
| Return visit (30+ min) | 11 | $950 | $86 |
Who their Medicare patients are
283 Original Medicare patients in 2024. Average age 61 · Under 65 48% · Women 44% · Also on Medicaid 62% · Health risk score 4.97. Above the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 65% · Coronary heart disease 41% · Heart failure 36% · Atrial fibrillation 25% · Depression 23% · Cancer 11% · COPD 10% · Stroke 9% · Dementia 5%.
The office billed $440,712, Medicare allowed $96,283 and paid $72,135; for 929 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 283 | 929 | 61 | 4.97 | $440,712 | $72,135 |
| 2023 | 370 | 930 | 59 | 5.48 | $606,263 | $99,407 |
| 2022 | 295 | 782 | 60 | 4.49 | $502,859 | $82,178 |
| 2021 | 260 | 676 | 59 | 4.61 | $437,522 | $73,976 |
| 2020 | 277 | 595 | 58 | 5.07 | $376,293 | $54,915 |
| 2019 | 287 | 416 | 59 | 5.84 | $162,984 | $33,000 |
| 2018 | 280 | 503 | 58 | 6.63 | $143,484 | $36,675 |
| 2017 | 404 | 774 | 59 | 7.39 | $229,868 | $56,580 |
| 2016 | 417 | 692 | 58 | 7.08 | $215,046 | $55,453 |
| 2015 | 471 | 908 | 58 | 6.83 | $271,745 | $74,798 |
| 2014 | 514 | 1,182 | 58 | 6.42 | $358,038 | $93,655 |
| 2013 | 461 | 1,013 | 57 | 6.79 | $295,539 | $85,604 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Long return visit (40+ min) | 165 | $45,015 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $19,609 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 54 | $7,015 | $68 |
| New patient visit (60+ min) | 44 | $6,422 | $146 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $5,390 | $142 |
| Telephone medical discussion with physician, 21-30 minutes | 30 | $3,453 | $80 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,309 | $114 |
| Long return visit (40+ min) | 13 | $1,972 | $141 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,544 | $103 |
| Return visit (30+ min) | 15 | $1,389 | $87 |
2022: 8 services
| Long return visit (40+ min) | 135 | $36,131 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 70 | $21,736 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,227 | $174 |
| Telephone medical discussion with physician, 21-30 minutes | 35 | $4,195 | $81 |
| New patient visit (60+ min) | 26 | $4,081 | $157 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,538 | $118 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,482 | $82 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,295 | $108 |
2021: 7 services
| Long return visit (40+ min) | 147 | $42,531 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $11,749 | $94 |
| Dialysis procedure including 1 evaluation | 21 | $5,385 | $80 |
| New patient visit (60+ min) | 25 | $3,650 | $146 |
| Telephone medical discussion with physician, 21-30 minutes | 26 | $3,340 | $74 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,368 | $182 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,362 | $91 |
2020: 7 services
| Long return visit (40+ min) | 137 | $18,467 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $15,233 | $96 |
| Return visit (30+ min) | 57 | $5,842 | $71 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,591 | $185 |
| New patient visit (60+ min) | 18 | $2,472 | $137 |
| Telephone medical discussion with physician, 21-30 minutes | 26 | $2,189 | $71 |
| New patient visit (45+ min) | 15 | $1,690 | $113 |
2019: 7 services
| Long return visit (40+ min) | 78 | $8,027 | $98 |
| Return visit (30+ min) | 100 | $7,722 | $70 |
| Hemodialysis procedure with physician evaluation | 46 | $5,416 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $3,831 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,750 | $125 |
| New patient visit (45+ min) | 16 | $1,893 | $118 |
| Short return visit (20+ min) | 27 | $1,329 | $46 |
2018: 5 services
| Return visit (30+ min) | 162 | $13,903 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $8,212 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 39 | $5,168 | $120 |
| New patient visit (45+ min) | 44 | $4,733 | $108 |
| Hemodialysis procedure with physician evaluation | 40 | $2,942 | $61 |
2017: 7 services
| Return visit (30+ min) | 177 | $13,500 | $65 |
| Hemodialysis procedure with physician evaluation | 89 | $10,651 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 60 | $9,717 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 66 | $8,954 | $118 |
| Long return visit (40+ min) | 84 | $7,505 | $86 |
| New patient visit (45+ min) | 44 | $4,428 | $101 |
| Short return visit (20+ min) | 14 | $611 | $44 |
2016: 7 services
| Long return visit (40+ min) | 236 | $22,538 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 72 | $10,936 | $62 |
| Hemodialysis procedure with physician evaluation | 74 | $7,748 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $4,201 | $120 |
| Return visit (30+ min) | 50 | $4,118 | $65 |
| New patient visit (45+ min) | 29 | $3,217 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,267 | $91 |
2015: 8 services
| Long return visit (40+ min) | 161 | $16,746 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 68 | $14,213 | $65 |
| Return visit (30+ min) | 149 | $11,892 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $9,432 | $93 |
| Hemodialysis procedure with physician evaluation | 68 | $6,740 | $65 |
| New patient visit (45+ min) | 47 | $5,509 | $117 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 49 | $5,350 | $94 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,520 | $126 |
2014: 8 services
| Long return visit (40+ min) | 205 | $20,776 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 97 | $18,397 | $62 |
| Return visit (30+ min) | 142 | $11,611 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $10,787 | $90 |
| Hemodialysis procedure with physician evaluation | 68 | $10,466 | $63 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 86 | $9,373 | $89 |
| New patient visit (45+ min) | 49 | $5,659 | $115 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 42 | $5,196 | $118 |
2013: 8 services
| Return visit (30+ min) | 244 | $29,273 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 84 | $22,047 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 75 | $10,452 | $119 |
| Long return visit (40+ min) | 58 | $7,177 | $122 |
| New patient visit (45+ min) | 46 | $6,450 | $140 |
| Hemodialysis procedure with physician evaluation | 62 | $5,807 | $62 |
| Long return visit (40+ min) | 16 | $1,507 | $94 |
| Return visit (30+ min) | 12 | $869 | $67 |
Medicaid work
$27,921 in 2024
Medicaid paid $27,921 for 293 billed services this clinician did in 2024, up to 39 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 223 | $24,675 |
| New patient visit (60+ min) | 12 | $2,772 |
| Telehealth transmission, per minute, professional services bill separately | 58 | $474 |
| 2024 | 293 | 3 | 39 | $27,921 |
| 2023 | 639 | 5 | 42 | $42,910 |
| 2022 | 597 | 5 | 37 | $37,702 |
| 2021 | 291 | 4 | 30 | $18,957 |
| 2020 | 140 | 4 | 24 | $7,347 |
| 2019 | 80 | 2 | 28 | $2,641 |
| 2018 | 66 | 1 | 18 | $230 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 384 | $34,755 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 70 | $4,796 |
| Telehealth originating site facility fee | 47 | $2,009 |
| Telehealth transmission, per minute, professional services bill separately | 126 | $1,129 |
| Measurement of magnesium | 12 | $221 |
2022
| Long return visit (40+ min) | 332 | $29,182 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 72 | $4,658 |
| Telehealth originating site facility fee | 81 | $2,972 |
| Telehealth transmission, per minute, professional services bill separately | 98 | $764 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 14 | $126 |
2021
| Long return visit (40+ min) | 209 | $18,126 |
| Telehealth originating site facility fee | 52 | $581 |
| Measurement of magnesium | 15 | $147 |
| Phosphorus inorganic (phosphate) | 15 | $103 |
2020
| Long return visit (40+ min) | 97 | $6,549 |
| Return visit (30+ min) | 19 | $758 |
| Hospital outpatient clinic visit for assessment and management of a patient | 12 | $40 |
| Telehealth originating site facility fee | 12 | $0 |
2019
| Long return visit (40+ min) | 38 | $2,482 |
| Return visit (30+ min) | 42 | $159 |
2018
| Return visit (30+ min) | 66 | $230 |
Drugs they prescribed that Part D paid
$171,389
Pharmacies billed $171,389 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,364) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
1,172 generic and 143 brand-name prescriptions · $171,389 in drug cost · 133 antibiotic prescriptions to 61 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lokelma | 32 | $34,087 | $1,065 |
| Valganciclovir | 62 | $18,430 | $297 |
| Everolimus | 13 | $18,041 | $1,388 |
| Envarsus Xr | 12 | $17,463 | $1,455 |
| Cinacalcet | 34 | $16,126 | $474 |
See all 32 drugs
| Lokelma | 32 | $34,087 | $1,065 |
| Valganciclovir | 62 | $18,430 | $297 |
| Everolimus | 13 | $18,041 | $1,388 |
| Envarsus Xr | 12 | $17,463 | $1,455 |
| Cinacalcet | 34 | $16,126 | $474 |
| Tacrolimus | 60 | $10,422 | $174 |
| Mycophenolate Mofetil | 37 | $6,598 | $178 |
| Mycophenolic Acid | 16 | $5,491 | $343 |
| Humalog Kwikpen U-100 | 18 | $2,838 | $158 |
| Prednisone | 244 | $1,459 | $6 |
| Methenamine Hippurate | 13 | $1,398 | $108 |
| Nano 2nd Gen Pen Needle | 16 | $1,202 | $75 |
| Ultra-Fine Nano Pen Needle | 17 | $1,099 | $65 |
| Lantus Solostar | 11 | $943 | $86 |
| Nifedipine Er | 19 | $804 | $42 |
| Entecavir | 28 | $541 | $19 |
| Hydralazine | 26 | $492 | $19 |
| Sulfamethoxazole-Trimethoprim | 91 | $453 | $5 |
| Calcitriol | 33 | $439 | $13 |
| Omeprazole | 53 | $369 | $7 |
| Tamsulosin | 27 | $262 | $10 |
| Potassium Chloride | 11 | $259 | $24 |
| Amlodipine Besylate | 57 | $173 | $3 |
| Fluconazole | 23 | $126 | $5 |
| Carvedilol | 30 | $116 | $4 |
| Losartan | 50 | $113 | $2 |
| Pantoprazole | 11 | $96 | $9 |
| Lisinopril | 20 | $88 | $4 |
| Ciprofloxacin | 17 | $65 | $4 |
| Furosemide | 15 | $58 | $4 |
| Famotidine | 14 | $49 | $3 |
| Rosuvastatin | 11 | $19 | $2 |
Year by year
| 2024 | 1,364 | 259 | 0% (0) | 10% | $171,389 |
| 2023 | 1,685 | 326 | None | 9% | $232,114 |
| 2022 | 1,855 | 337 | 0% (0) | 8% | $287,744 |
| 2021 | 2,053 | 348 | None | 11% | $346,291 |
| 2020 | 1,292 | 288 | None | 12% | $257,591 |
| 2019 | 383 | 81 | 0% (0) | 13% | $26,392 |
| 2018 | 479 | 47 | 0% (0) | 19% | $42,838 |
| 2017 | 288 | 40 | None | None | $50,711 |
| 2016 | 255 | 31 | None | 25% | $25,414 |
| 2015 | 359 | 33 | None | 19% | $24,145 |
| 2014 | 484 | 42 | None | 27% | $41,126 |
| 2013 | 926 | 51 | None | 30% | $105,515 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 35 drugs
| Cinacalcet | 49 | $35,562 | $726 |
| Valganciclovir | 85 | $26,758 | $315 |
| Tacrolimus | 94 | $21,696 | $231 |
| Envarsus Xr | 28 | $20,618 | $736 |
| Lokelma | 15 | $14,590 | $973 |
| Novolog Flexpen | 16 | $10,971 | $686 |
| Atovaquone | 12 | $8,816 | $735 |
| Mycophenolic Acid | 25 | $6,273 | $251 |
| Entecavir | 48 | $5,070 | $106 |
| Humalog Kwikpen U-100 | 14 | $4,431 | $316 |
| Mycophenolate Mofetil | 47 | $3,638 | $77 |
| Nano 2nd Gen Pen Needle | 18 | $3,082 | $171 |
| Prednisone | 327 | $2,240 | $7 |
| Nifedipine Er | 13 | $2,124 | $163 |
| Methenamine Hippurate | 15 | $2,065 | $138 |
| Losartan | 59 | $1,359 | $23 |
| Sulfamethoxazole-Trimethoprim | 109 | $984 | $9 |
| Omeprazole | 81 | $863 | $11 |
| Amlodipine Besylate | 66 | $688 | $10 |
| Ultra-Fine Nano Pen Needle | 11 | $494 | $45 |
| Fluconazole | 37 | $431 | $12 |
| Tamsulosin | 28 | $394 | $14 |
| Calcitriol | 42 | $360 | $9 |
| Potassium Chloride | 11 | $270 | $25 |
| Carvedilol | 20 | $257 | $13 |
| Furosemide | 40 | $256 | $6 |
| Labetalol | 11 | $255 | $23 |
| Metoprolol | 28 | $226 | $8 |
| Hydralazine | 11 | $197 | $18 |
| Clonidine | 13 | $152 | $12 |
| Pravastatin | 11 | $135 | $12 |
| Pantoprazole | 11 | $128 | $12 |
| Ciprofloxacin | 23 | $110 | $5 |
| Lisinopril | 18 | $101 | $6 |
| Atorvastatin | 12 | $86 | $7 |
2022: 33 drugs
| Cinacalcet | 66 | $56,606 | $858 |
| Valganciclovir | 55 | $33,628 | $611 |
| Tacrolimus | 173 | $29,627 | $171 |
| Nulojix | 14 | $27,659 | $1,976 |
| Mycophenolate Mofetil | 129 | $18,768 | $145 |
| Eliquis | 21 | $12,670 | $603 |
| Lokelma | 19 | $11,583 | $610 |
| Mycophenolic Acid | 32 | $8,495 | $265 |
| Humalog Kwikpen U-100 | 15 | $4,451 | $297 |
| Prednisone | 354 | $2,442 | $7 |
| Entecavir | 31 | $1,883 | $61 |
| Nifedipine Er | 20 | $1,584 | $79 |
| Hydralazine | 24 | $649 | $27 |
| Losartan | 71 | $583 | $8 |
| Calcitriol | 30 | $579 | $19 |
| Sulfamethoxazole-Trimethoprim | 85 | $573 | $7 |
| Tamsulosin | 37 | $494 | $13 |
| Amlodipine Besylate | 54 | $440 | $8 |
| Omeprazole | 58 | $395 | $7 |
| Carvedilol | 43 | $340 | $8 |
| Furosemide | 64 | $294 | $5 |
| Fluconazole | 26 | $227 | $9 |
| Atorvastatin | 26 | $191 | $7 |
| Cephalexin | 19 | $181 | $10 |
| Metoprolol | 39 | $180 | $5 |
| Pravastatin | 17 | $160 | $9 |
| Pantoprazole | 17 | $120 | $7 |
| Clonidine | 11 | $119 | $11 |
| Famotidine | 14 | $113 | $8 |
| Lisinopril | 22 | $81 | $4 |
| Ciprofloxacin | 15 | $79 | $5 |
| Glipizide | 15 | $71 | $5 |
| Amiodarone | 11 | $41 | $4 |
2021: 38 drugs
| Tacrolimus | 212 | $56,692 | $267 |
| Valganciclovir | 100 | $45,190 | $452 |
| Lokelma | 42 | $34,588 | $824 |
| Nulojix | 17 | $33,386 | $1,964 |
| Cinacalcet | 39 | $27,417 | $703 |
| Mycophenolic Acid | 49 | $22,204 | $453 |
| Mycophenolate Mofetil | 105 | $18,541 | $177 |
| Novolog Flexpen | 31 | $15,922 | $514 |
| Lantus Solostar | 18 | $6,127 | $340 |
| Lamivudine Hbv | 35 | $4,402 | $126 |
| Humalog Kwikpen U-100 | 20 | $3,265 | $163 |
| Calcitriol | 36 | $2,903 | $81 |
| Basaglar Kwikpen U-100 | 11 | $2,898 | $263 |
| Nifedipine Er | 42 | $2,080 | $50 |
| Prednisone | 241 | $1,534 | $6 |
| Dapsone | 20 | $1,296 | $65 |
| Sulfamethoxazole-Trimethoprim | 128 | $951 | $7 |
| Losartan | 89 | $819 | $9 |
| Omeprazole | 86 | $759 | $9 |
| Midodrine | 11 | $716 | $65 |
| Ultra-Fine Nano Pen Needle | 11 | $673 | $61 |
| Fluconazole | 42 | $600 | $14 |
| Amlodipine Besylate | 72 | $530 | $7 |
| Hydralazine | 22 | $461 | $21 |
| Tamsulosin | 44 | $439 | $10 |
| Entecavir | 12 | $332 | $28 |
| Metoprolol | 46 | $300 | $7 |
| Potassium Chloride | 17 | $227 | $13 |
| Atorvastatin | 29 | $223 | $8 |
| Carvedilol | 23 | $210 | $9 |
| Furosemide | 37 | $158 | $4 |
| Cephalexin | 14 | $149 | $11 |
| Hydroxyzine | 13 | $147 | $11 |
| Pantoprazole | 16 | $143 | $9 |
| Pravastatin | 12 | $137 | $11 |
| Famotidine | 13 | $131 | $10 |
| Ciprofloxacin | 22 | $124 | $6 |
| Lisinopril | 19 | $98 | $5 |
2020: 29 drugs
| Tacrolimus | 120 | $41,476 | $346 |
| Cinacalcet | 47 | $38,213 | $813 |
| Valganciclovir | 58 | $26,517 | $457 |
| Mycophenolic Acid | 22 | $12,111 | $551 |
| Mycophenolate Mofetil | 62 | $8,802 | $142 |
| Lamivudine Hbv | 38 | $7,876 | $207 |
| Januvia | 12 | $5,934 | $494 |
| Basaglar Kwikpen U-100 | 12 | $2,982 | $249 |
| Lantus Solostar | 14 | $2,853 | $204 |
| Nifedipine Er | 43 | $2,100 | $49 |
| Cyclosporine Modified | 12 | $1,717 | $143 |
| Ultra-Fine Nano Pen Needle | 11 | $1,297 | $118 |
| Prednisone | 140 | $947 | $7 |
| Flunisolide | 12 | $654 | $54 |
| Omeprazole | 59 | $519 | $9 |
| Sulfamethoxazole-Trimethoprim | 58 | $415 | $7 |
| Losartan | 34 | $355 | $10 |
| Amlodipine Besylate | 53 | $328 | $6 |
| Tamsulosin | 21 | $292 | $14 |
| Hydralazine | 15 | $284 | $19 |
| Enalapril Maleate | 19 | $241 | $13 |
| Metoprolol | 18 | $236 | $13 |
| Furosemide | 35 | $210 | $6 |
| Pantoprazole | 19 | $207 | $11 |
| Fluconazole | 22 | $186 | $8 |
| Atorvastatin | 20 | $182 | $9 |
| Ciprofloxacin | 26 | $158 | $6 |
| Glipizide | 19 | $136 | $7 |
| Lisinopril | 24 | $118 | $5 |
2019: 9 drugs
| Tacrolimus | 18 | $5,970 | $332 |
| Nifedipine Er | 41 | $1,449 | $35 |
| Flunisolide | 14 | $762 | $54 |
| Alcohol Pads | 14 | $668 | $48 |
| Prednisone | 37 | $273 | $7 |
| Tamsulosin | 22 | $231 | $11 |
| Furosemide | 33 | $201 | $6 |
| Famotidine | 11 | $131 | $12 |
| Amlodipine Besylate | 28 | $98 | $4 |
2018: 14 drugs
| Eliquis | 11 | $6,361 | $578 |
| Lantus Solostar | 12 | $2,748 | $229 |
| Nifedipine Er | 42 | $2,145 | $51 |
| Nateglinide | 19 | $1,133 | $60 |
| Flunisolide | 13 | $950 | $73 |
| Alcohol Pads | 11 | $551 | $50 |
| Enalapril Maleate | 13 | $426 | $33 |
| Tamsulosin | 33 | $418 | $13 |
| Prednisone | 49 | $324 | $7 |
| Metoprolol | 25 | $196 | $8 |
| Atorvastatin | 14 | $161 | $12 |
| Carvedilol | 23 | $134 | $6 |
| Furosemide | 16 | $101 | $6 |
| Amlodipine Besylate | 30 | $98 | $3 |
2017: 6 drugs
| Sensipar | 13 | $10,928 | $841 |
| Esomeprazole Magnesium | 15 | $1,967 | $131 |
| Valsartan | 13 | $249 | $19 |
| Prednisone | 39 | $174 | $4 |
| Amlodipine Besylate | 20 | $146 | $7 |
| Furosemide | 15 | $80 | $5 |
2016: 4 drugs
| Sensipar | 12 | $8,543 | $712 |
| Valsartan | 20 | $421 | $21 |
| Warfarin | 16 | $96 | $6 |
| Prednisone | 17 | $72 | $4 |
2015: 14 drugs
| Sensipar | 15 | $9,102 | $607 |
| Valsartan | 13 | $582 | $45 |
| Nifedipine Er | 12 | $464 | $39 |
| Nifedical Xl | 12 | $411 | $34 |
| Alcohol Pads | 11 | $245 | $22 |
| Tamsulosin | 12 | $162 | $14 |
| Glipizide Er | 11 | $106 | $10 |
| Prednisone | 21 | $103 | $5 |
| Finasteride | 12 | $99 | $8 |
| Metoprolol | 15 | $93 | $6 |
| Atorvastatin | 11 | $89 | $8 |
| Simvastatin | 11 | $77 | $7 |
| Amlodipine Besylate | 19 | $70 | $4 |
| Furosemide | 13 | $32 | $2 |
2014: 20 drugs
| Sensipar | 15 | $8,787 | $586 |
| Diovan | 30 | $4,715 | $157 |
| Lantus Solostar | 11 | $3,530 | $321 |
| Nexium | 11 | $2,649 | $241 |
| Nifedical Xl | 12 | $686 | $57 |
| Metoprolol | 19 | $530 | $28 |
| Nifedipine Er | 11 | $486 | $44 |
| Atorvastatin | 12 | $341 | $28 |
| Easy Touch Pen Needle | 12 | $329 | $27 |
| Gabapentin | 14 | $321 | $23 |
| Calcitriol | 14 | $298 | $21 |
| Clonidine | 23 | $288 | $13 |
| Tamsulosin | 12 | $139 | $12 |
| Amlodipine Besylate | 21 | $137 | $7 |
| Clopidogrel | 18 | $130 | $7 |
| Furosemide | 25 | $125 | $5 |
| Prednisone | 14 | $85 | $6 |
| Famotidine | 17 | $80 | $5 |
| Atenolol | 17 | $64 | $4 |
| Hydrochlorothiazide | 13 | $20 | $2 |
2013: 28 drugs
| Sensipar | 34 | $20,343 | $598 |
| Cellcept | 12 | $17,600 | $1,467 |
| Lantus | 18 | $5,314 | $295 |
| Tacrolimus | 17 | $5,297 | $312 |
| Lantus Solostar | 17 | $4,511 | $265 |
| Nexium | 20 | $4,322 | $216 |
| Diovan | 28 | $3,836 | $137 |
| Advair Diskus | 11 | $3,822 | $347 |
| Novolog Flexpen | 11 | $3,471 | $316 |
| Nifedipine Er | 45 | $1,787 | $40 |
| Metoprolol | 38 | $1,187 | $31 |
| Clopidogrel | 30 | $1,112 | $37 |
| Mycophenolate Mofetil | 21 | $943 | $45 |
| Nifedical Xl | 14 | $830 | $59 |
| Atorvastatin | 32 | $662 | $21 |
| Omeprazole | 26 | $443 | $17 |
| Calcitriol | 11 | $443 | $40 |
| Novofine | 11 | $372 | $34 |
| Tamsulosin | 21 | $337 | $16 |
| Clonidine | 15 | $223 | $15 |
| Amlodipine Besylate | 37 | $198 | $5 |
| Enalapril Maleate | 22 | $183 | $8 |
| Prednisone | 61 | $175 | $3 |
| Famotidine | 24 | $169 | $7 |
| Furosemide | 38 | $154 | $4 |
| Metoprolol | 20 | $141 | $7 |
| Atenolol | 24 | $133 | $6 |
| Allopurinol | 14 | $75 | $5 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| SANOFI US SERVICES INC. · A Multi-Cohort, Randomized, Phase 2, Open-Label Study To Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of Bivv020 for Prevention and Treatment of Antibody-Mediated Rejection in Adult Kidney Transplant Recipients. · 2025 | Their institution | $63,061 |
| SANOFI US SERVICES INC. · A Multi-Cohort, Randomized, Phase 2, Open-Label Study To Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of Bivv020 for Prevention and Treatment of Antibody-Mediated Rejection in Adult Kidney Transplant Recipients. · 2024 | Their institution | $24,626 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 82.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1104001718
- Licence
- CA C154027, NY 003757California C154027: Current · expires 2027-11-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X); Student in a training program (390200000X)
- Mailing address
- 400 Parnassus Ave, San Francisco, CA, 94143
- NPI first listed
- 2008-01-02
- NPI last updated
- 2020-12-08
- NPI record certified
- 2020-12-08
This is when the NPI record was last certified, not a medical board exam.